Clinical Pharmacists In Oncology: Improving the Patient Outcomes and Drug Safety

The broadening application of multi-agent chemotherapy, targeted therapies, immunotherapies, and oral anticancer agents have complicated cancer treatment. Though these innovations have increased the number of people who survive, they have also increased the risk of medication related errors, adverse drug reactions and limitations of either treatment adherence and of treating toxicity. In that regard, the concept of clinical pharmacist integration into oncology care teams has become one of the most important solutions to patient outcomes and medication safety improvements. The presented narrative review is a synthesis of the current evidence regarding the role of clinical pharmacists in oncology with emphasis on their contributions to drug safety, clinical outcomes, economic efficiency, and patient-centred care. A literature review was performed to identify peer-reviewed interventions, published in the past five years (20142024), which focused on phyto-based interventions to examine the pharmacist-led intervention in the context of inpatient, ambulatory, oral chemotherapy, and investigational drug service. Qualitative synthesis of findings was made into major thematic areas. That fact illustrates that clinical pharmacists can have a leading part in decrease in chemotherapy administrative and dispensing mistakes, enhance medication reconciliation, treat toxicity linked with treatment, and improve treatment adherence to intravenous and oral anticancer treatments. Pharmacist intervention also relates to enhanced clinical results, such as optimisation of dosing, lessening of interruptions in treatment and enhancing the management of symptoms. Moreover, the pharmacist-led interventions can be used to minimise costs by decreasing hospitalisations and adverse drug events; as well as improve the humanistic outcomes, including patient satisfaction and quality of life. The review also emphasizes the increased role of pharmacists in the management of treating emerging oncology therapies, such immunotherapies and CAR T cell therapies, which are associated with unique monitoring and toxicity control. Irrespective of strong evidence of value, obstacles associated with workforce constraint, training inconsistency, regulation limitations, and unstandardised outcome assessment continue to exist. To conclude, oncology care encompassing clinical pharmacists is a high-value, evidence-based method of enhancing medication safety, clinical outcome, and patient-centered outcomes. The implementation models need to be strengthened, the training should be standardised, and more high-quality research should be conducted to bring the potential of oncology pharmacy practice in various healthcare environments to the full extent..